Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In the present experiment, cellular suspension, extracted from osteogenic sarcoma tissue removed from patients in operation, was used to immunize BABL/cmouse. The immunized murine spleen cells and murine myeloma cells were fused. The three lines of the hybridoma cells were produced by fusion and were screened by the method of PAP immunoperoxidase. Three hybridomas (MOG 1, MOF 6, MoC 4) reacted with osteogenic sarcoma but not with the normal synovium. MOF 6 reacted with rhabdomyosarcoma, fibrosarcoma, undifferentiated round cell sarcoma and melanoma but not with other tumors and normal tissues. MOG 1 and MOC 4 reacted with more tumors and tissues. The subclasses of MOF 6 and MOG 1 were identified. Both antibodies are IgG 1. Ascites developed in 10 days after two hybridomas were injected respectively into the murine peritoneal cavities. By more extensive research, the monoclonal antibodies may be used in many clinical and experimental works.
 ...
PMID:[Experimental study of the murine monoclonal antibodies of anti-human osteogenic sarcoma]. 181 44

Monoclonal antibodies (MAb) to the thymidine analog 5-bromo-2'-deoxyuridine (BrdUrd) and to horseradish peroxidase (HRPO) have been produced and characterized. On the basis of Mab to HRPO, complexes of the antibodies and HRPO (PAP-complexes) for immunochemical investigations are prepared. The possibility to identify proliferating cells in cultures of mouse myeloma Sp2/0 and mouse fibroblasts NIH 3T3 using Mab to BrdURd by the PAP-method is shown. The conditions of performing the analysis were optimized. The effect of various techniques ot cell fixation and cell DNA denaturation on cell morphology and on specific staining of nuclei of BrdUrd-containing cells in investigated.
 ...
PMID:[The demonstration of proliferating cells by using monoclonal antibodies to 5-bromo-2'-deoxyuridine in the peroxidase-antiperoxidase method]. 210 85

Lymphocytes from regional lymph nodes of patients with ovarian carcinoma were immortalized by fusing them with a nonsecreting cell line of murine myeloma (Sp2/0-Ag14). The fusion rate was 0-87.5%. By early cloning and recloning, a hybrid cell line, named HMD4, was established. It has stably secreted human IgG for more than 15 months. Chromosome analysis showed the characteristics of human-mouse hybridoma. The cells of HMD4 were injected into the abdominal cavities of nude mice and 2-3 weeks later large quantities of ascites were obtained. Human IgG of lambda light chain was detected and purified from the ascites. The specificity of HMD4 human McAb was tested by ABC or PAP immunoperoxidase stainings of paraffin-embedded tissue sections, cryostat sections, cell smears of various tissues and different cancer cell lines. 60.5% (26/43) of epithelial ovarian cancers was positive, while nonepithelial ovarian cancers, most cancers from other organs and almost all nonmalignant and normal tissues were negative. The molecular weight of the antigen recognized by HMD4 was 55 KDa determined by Western blotting. The problems of maintaining the IgG secreting function of human-mouse hybridoma and its screening were also discussed.
 ...
PMID:A human monoclonal antibody HMD4 against ovarian carcinoma associated antigen. 211 60

Spleen cells from BALB/c mice previously immunized with B-lymphoblastoid cell line RPMI-1788 were fused with P3-X-63-Ag8.653 myeloma cells. Monoclonal antibodies (Ab) IPO-4 were screened on 18 cell lines by the indirect immuno-fluorescence method. Cryostat sections of tissues were stained according to the PAP technique. The Mab IPO-4 were tested for reactivity with blood cells of 17 healthy persons and 102 patients with chronic lymphocytic leukemia, acute lymphoblastic and myeloblastic leukemias, hairy cell leukemia, multiple myeloma, non-Hodgkin's lymphomas and Hodgkin's disease and mitogen stimulated lymphocytes. MAb IPO-4 were found to be directed against antigen expressed on activated T and B cells.
 ...
PMID:[Monoclonal antibodies IPO-4 recognizing antigen-activated human T and B lymphocytes]. 234 19

An autopsy case of primary cutaneous plasmacytoma with very unusual extensive skin involvement resulting in death 9 months later, was reported. A 75-year-old female was admitted to our hospital in November, 1985 because of an enlarging skin nodule on the right neck of 5 month's duration. The nodule was a 5 x 7 x 4-cm, firm and mobile mass. Light- and electron-microscopic studies of its biopsy specimen revealed a cutaneous plasmacytoma which was composed of dense aggregates of plasma cells. Cytogenic study on the biopsy specimen revealed hypotetraploid and structural abnormalities such as 7q+, 11q+ and 20q+. After radiotherapy, the right neck nodule became smaller, but subcutaneous indurations with erosions extended to the surrounding skin. The biopsy specimen of these skin lesions microscopically revealed massive infiltrations of plasma cells in the dermis. The PAP method revealed a definite evidence of monoclonal kappa light chain production by these cells. 3H-thymidine were incorporated in 5.6% of the plasma cells. The skin lesions were refractory to chemotherapy and gradually extended. The clinical course showed a progressive one leading to persistent deterioration and she died in August, 1986. Repeated examinations including immunoelectrophoresis of serum and concentrated urine, bone marrow aspirations and skeletal x-ray films, excluded the diagnosis of myeloma. At autopsy, massive infiltrations of plasma cells in the skin of chest wall and neck, small metastatic tumors in the liver and bilateral axillary lymph nodes were found, but there was no evidence of bone marrow involvement.
 ...
PMID:[An autopsy case of primary cutaneous plasmacytoma]. 266 64

Bone marrow aspirates from 10 patients with multiple myeloma (6 IgG myeloma, 3 IgA myeloma, 1 Bence Jones myeloma) were examined for nucleolus-associated localization of J chains. On light microscopy using the PAP method, almost all or a significant number of myeloma cells exhibited intranuclear spots stained with anti-J chains in 3 (IgG myeloma) out of the 8 cases positive for cytoplasmic J chains. In contrast, the nucleus of myeloma cells examined was constantly negative for anti-heavy and -light chains. Immunoelectron microscopically, J chain was identified as dicrete round electron-dense precipitates, corresponding to the whole nucleolus, and as sparsely distributed, small electron-dense deposits in the nucleus. In addition, some connections were found between nuclear and nucleolar electron-dense precipitates. Several possible explanations have been proposed to account for this localization of J chains.
 ...
PMID:Nucleolus-associated J chains in myeloma cells. 310 Nov 68

A human myeloma cell line designated LOPRA-1 has been established from ascites fluid containing malignant plasma cells of a patient with IgA2/kappa multiple myeloma. The cultured cells which are Epstein-Barr virus (EBV) negative have retained the morphological, cytochemical, ultrastructural and immunophenotypical features of well-differentiated plasma cells. They express the plasma cell antigen PCA-1, the antigens CD28 (Kolt-2) and CD38 (OKT10), the transferrin-receptor (OKT9), and some epitopes of the CD24 antigen (HB8, VIB E3), but are negative for surface immunoglobulins. HLA class II antigens (HLA-DP, -DQ, -DR) and other B-cell markers such as CD10 (CALLA), CD19 (B4), CD20 (B1), CD21 (B2), CD22 (HD39), CD23 (MHM6), CD37 (BL14) and CD39 (G28-8) as analysed by both flow cytometry and immunocytochemistry (PAP/APAAP). With respect to immunoglobulin synthesis, two stable clones were selected by single cell cloning: clone LOPRA-1/5 synthesizes large amounts of alpha 2 heavy and kappa light chains, but secretes only small amounts of these molecules, whereas clone LOPRA-1/4 is clearly devoid of intracellular immunoglobulin heavy and light chains and thus appears to be a chain loss variant. Cytogenetic analysis revealed a pseudotriploid phenotype with several structurally abnormal marker chromosomes: 3n + -, 70, XX, -X, -1, -4, -6, -8, -8, -13, -16, +7, +18, +21, +i(1q), +i(1q), +6q-, +3mar.
 ...
PMID:Establishment and characterization of a permanent human IgA2/kappa myeloma cell line. 313 91

A human immunoglobulin M (IgM) antibody secreting hybridoma, HMG1, has been established and studied for its reactivity against human gastric cancer cells. Lymphocytes isolated from a regional lymph node of patient with gastric adenocarcinoma were fused with mouse myeloma cells NS-1. Supernatants from the generated human-mouse hybrids were first screened for immunoglobulin production by ELISA. The identified human IgM-secreting hybridomas were expanded and subcloned for further analysis or cryopreservation. The screening for binding of antibodies to a panel of human cancer cell lines and normal fibroblast was carried out with PAP or indirect immunofluorescence stain. The selected hybridoma, HMG1 after being cloned three times, was stable in secreting IgM (about 4 micrograms/1 x 10(6) cells) for more than 9 months. Large amount of ascites was obtained by injecting this hybrid to BALB/C nude mice pretreated with anti-lymphocyte serum and pristane. The ascitic fluid contained 5-19 mg human Ig/ml. Subsequently this IgM was extracted from ascitic fluid by saturated ammonium sulphate solution. This crude extract was further purified with immuno-affinity chromatography. Both this purified ascite-IgM as well as IgM from HMG1 supernatant would react with gastric cancer cell line BGC-823 but not with human normal fibroblasts 350Q by PAP or immunofluorescence analysis. The human HMG1-IgM reacted with gastric cancer cells on paraffin embedded tissue section but did not react with normal gastric mucosa cells. HMG1-IgM had some complement dependent cytotoxicity against BGC-823. These results suggest that the establishment of anticancer human monoclonal antibodies with human-mouse hybridoma technique be feasible. There is a possibility for clinical applications of this human monoclonal antibody in the future.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Study of anticancer human monoclonal antibody--establishment of human monoclonal antibody to gastric cancer by human-mouse hybridoma]. 324 78

By using both direct and indirect immunofluorescence technics and the PAP method, the authors observed an unusual immunocytochemical staining pattern in myeloma cells producing IgG 1(lambda). J chains were localized mainly as intranuclear spots, compared with gamma and lambda chains that are diffusely distributed in the cytoplasm with dense perinuclear accumulation. The present findings on the location, size, and number of the intranuclear spots suggest that J chains are nucleolus associated. The authors hypothesize that J chains are synthesized in the cytoplasm and transported into the nucleolus, where they associate with nucleolar proteins, or that they are synthesized within the nucleolus, which participates in biogenesis of ribosomes.
 ...
PMID:Nucleolus-associated localization of J chains in IgG 1(lambda)-producing myeloma cells. 392 15

Hybridoma cells secreting anti-PAP were produced by fusion of NS-1 myeloma cells with spleen cells from immunized Balb/c mice. Three of 32 hybrids secreted antibodies. Dilution cloning of the two hybrids producing the highest antibody titres showed that each antibody was monoclonal. One clone from each hybrid (clones ES2 and ES8) was selected for further study. The specificity of the antibodies appeared satisfactory, no inhibition of 125I-PAP binding to antibody being seen with extracts of bone, intestine, kidney, leucocytes, liver or lung. The association constants of the antibodies from ES2 and ES8 were 1.7 X 10(8) and 1.7 X 10(9) l/mol respectively, both were of the IgG1 class. For the immunoradiometric (IRMA) assay of serum PAP 125I-labelled monoclonal antibody was incubated with serum and the PAP-labelled antibody complex was separated by addition of solid-coupled polyclonal anti-PAP. The wide working range of the response curve (0.3-400 micrograms/l) and the rapid analysis time (4 h) offer practical advantages over RIA procedures. Clinical evaluation of the assay is in progress. ES8 antibody also appears to have good specificity for immunocytochemical applications. Localisation of micrometastases in bone in prostatic carcinoma was readily achieved.
 ...
PMID:The preparation, characterization and application of monoclonal antibodies to human prostatic acid phosphatase (PAP). 608 20


1 2 Next >>